Promethazine DM Should NOT Be Given to Patients with Congenital Glaucoma
Promethazine with dextromethorphan is contraindicated in patients with congenital glaucoma due to the anticholinergic properties of promethazine, which can precipitate or worsen angle-closure glaucoma. 1
Primary Contraindication: Anticholinergic Effects
The FDA drug label explicitly states that "drugs having anticholinergic properties should be used with caution in patients with narrow-angle glaucoma" 1. While this warning specifically mentions narrow-angle glaucoma, congenital glaucoma patients often have anatomical abnormalities that make them vulnerable to the same anticholinergic-induced complications.
Mechanism of Harm
- Promethazine's anticholinergic effects can cause pupillary dilation and relaxation of the ciliary muscle
- This can lead to:
- Increased intraocular pressure (IOP)
- Potential angle closure in susceptible eyes
- Acute glaucoma attacks
Recent case evidence demonstrates that even the dextromethorphan component alone can trigger bilateral acute angle-closure glaucoma, with one patient presenting with IOPs of 57 mmHg and 50 mmHg after just 5 days of OTC cold medication use 2.
Additional Safety Concerns in Pediatric Patients
Since congenital glaucoma is by definition a pediatric condition, the FDA's black box warnings are particularly relevant:
- Promethazine is absolutely contraindicated in children under 2 years of age 1
- For children ≥2 years: carries risk of fatal respiratory depression 1
- The extrapyramidal symptoms from promethazine can mask signs of serious underlying conditions 1
Evidence Synthesis
The literature consistently identifies antihistamines (including promethazine) as medications that can induce or precipitate angle-closure glaucoma 3. A comprehensive 2003 review specifically lists "histamine H₁ and H₂ receptor antagonists" among drug classes reported to induce acute angle-closure glaucoma, with cases of bilateral involvement and blindness 3.
Critical Pitfall to Avoid
Do not assume that oral formulations are safer than parenteral routes for glaucoma patients. The anticholinergic systemic effects occur regardless of administration route and pose the same risk to intraocular pressure.
Recommended Alternatives
For cough suppression in congenital glaucoma patients:
- Non-anticholinergic antitussives (e.g., guaifenesin for productive cough)
- Dextromethorphan alone may be considered with extreme caution and ophthalmologic consultation, given the case report of angle-closure 2, though this risk appears lower than with promethazine
For antihistamine needs:
- Consult pediatric ophthalmology before using any antihistamine
- Consider non-sedating, less anticholinergic alternatives if absolutely necessary
- Monitor IOP closely if any anticholinergic medication is unavoidable
The risk-benefit analysis clearly favors avoiding promethazine DM entirely in congenital glaucoma patients, as the potential for vision-threatening IOP elevation and acute glaucoma attacks outweighs any symptomatic benefit from cough or allergy suppression.